TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Summary

The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.

Timeline

Start

2020-09-11

Primary completion

2024-08-31

Completion

2026-01-31

Outcome

Met primary endpoint

paper Median PFS per composite criteria was significantly longer with TACE-C-R than with TACE PMID 41734362 ↗

paper hazard ratio, 0.34 [95% CI, 0.24 to 0.50], P < .001 PMID 41734362 ↗

Publications

• Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC, Zhang ZW, Guo JH, Cheng HT, Zhang Q, Lu J, Zeng YY, Lv WF, Xu H, Shao HB, Xu WG, Zhao XY, Gu SZ, Lin HL, Zheng WH, Piao LZ, Song YS, Zhao JB, Wang YC, Hou ZG, Sun Y, Guan N, Huang M, Yang WZ, Ji JS, Teng GJ. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026 Apr 10;44(11):959-969. doi: 10.1200/JCO-25-01796. Epub 2026 Feb 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral

Indications